Meeting Coverage >

EASD

Death Risk Elevated in Dementia Patients with Hypoglycemia

Target hypoglycemic episodes instead of HbA1c, researchers urge

Deaths from Non-Obesity-Related Cancers Higher in T2D

Even in some obesity-related malignancies, high BMI was inversely tied to cancer death

Heart Benefit Seen with GLP-1 RA Albiglutide

Significant reduction in myocardial infarctions; will drug be brought back to market?

In Brief: Four EASD Trials to Note

Aggressive therapy cuts range of risk factors; caffeine tied to mortality benefit; and more

CV Benefit from PCSK9 Drug Unaltered by Diabetes

Nor did evolocumab hike diabetes risk in FOURIER cohort

Dietary Sodium Tied to New-Onset Diabetes Risk

Higher rates of type 2 and late autoimmune diabetes in adults with increasing sodium

Sugar Substitutes: Not So Sweet for Glucose Absorption?

Artificial sweeteners may have negative effect on glycemic control

T2D Tied to Less Aortic Aneurysm Risk

Does diabetes somehow strengthen vessel wall?

Diabetes Targets Hard to Meet in Transgender Population

Hormone therapy tied to increased modifiable risks

Novel Intestinal Sleeve Improves Weight and T2D Control In Real World

Small U.K. study suggests benefits in real-world use

A1c, Weight Loss Benefit Seen With Exenatide-Glargine Combo

No increased risk for hypoglycemia reported

EASD Imposes Tight Security Outside, Embraces Twitter Inside

ADA overreacted to online slide sharing, EASD leaders say

Another GLP-1 Wins on Cardio Prevention

Novel semaglutide reduced major CV event risk in large outcomes trial

Januvia/Metformin Combo Gets Boost from Novel SGLT2

T2D patients uncontrolled on duo do better when adding ertugliflozin

CGM for T1D Reduces Hypoglycemia

Less time outside range for reduced hypo awareness patients in trial

Switching GLP-1 For DPP-4 Improves Net T2D Outcomes

Victoza bests Januvia for combo therapy on A1c, weight, hypoglycemia composite

EASD: Gestational Diabetes Guidelines Controversial

LISBON -- International guidelines on screening for gestational diabetes that will likely raise the prevalence of the condition have sparked questions over appropriate diagnostic tools and cost efficacy, researchers said here.